furaprevir

Furaprevir is an orally administered small molecule drug that acts as a hepatitis C virus (HCV) NS3/4A protease inhibitor. It was discovered and developed by TaiGen Biotechnology through rational drug design and extensive screening of over 1,500 compounds[1][5]. Furaprevir specifically targets the NS3/4A serine protease complex of HCV, which is essential for viral replication. By inhibiting this protease, furaprevir blocks the cleavage of the viral polyprotein into mature proteins necessary for HCV replication[5][7]. The drug has been investigated primarily for chronic hepatitis C infection in adults, including those who have not responded adequately to previous treatments[4]. Clinical trials have reached up to phase III in China and phase II in Taiwan and the United States[5][7].

Other names

Furaprevir [INN]UNII-0UMM44REU9UNII0UMM44REU9UNII 0UMM44REU90UMM44REU9